In order to establish the therapeutic potential of combined AKT and SGK3 inhibition in a breast cancer model, we tested cell proliferation in vitro and established xenografts in nude mice with BT‐474 cells, which are sensitive to Akt inhibitors when cultured in vitro (Sommer et al, 2013) and in which prolonged treatment with Akt inhibitors leads to upregulation of SGK3 (Fig 8A). Here, SGK3 is linked to breast cancer.